Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease

By S. Stein, M. Ott, S. Schultze-Strasser, A. Jauch, B. Burwinkel, A. Kinner, M. Schmidt, A. Krämer, J. Schwäble, H. Glimm and 18 more. Nature Medicine, 2010

770 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/038c9c9b8079ed418005a352d8087fe614fb68f2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. L. Ginn
2. I. Alexander
3. Michael Edelstein
4. M. Abedi
5. W. de Laat
6. H. Döhner
7. James E. Bradner
8. Stefan Gröschel

Citations in the corpus

• Gene therapy clinical trials worldwide to 2012 – an update (2013, background): “This was later determined to be caused by silencing of the transgene as a result of methylation of the viral promoter [41].”
• A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. (2014, background): “, 1988) and also represents an important insertional mutagenesis site in humans following gene therapy for X-linked granulomatous disease (Stein et al., 2010).”